Monopar Therapeutics MNPR 深 沪
等待开盘 07-06 09:30:00 美东时间
97.79
+2.760
+2.90%
华盛通- 最 高100.00
- 今 开95.44
- 成交量 18.83万股
- 最 低 93.59
- 昨 收 95.03
- 总市值 6.55亿
- 52周最高 105.00
- 市盈率 静 --
- 换手率 2.81%
- 52周最低 29.18
- 委 比 79.92%
- 总股本 669.91万
- 历史最高 240.00
- 量 比 1.02
- 振 幅 6.75%
- 历史最低 1.3695
- 每 手 1
- 风险率 16.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Bernstein上调闪迪目标价从1700美元升至3000美元；大摩上调谷歌-A目标价从375美元升至415美元
今日重点评级关注：Citizens：维持DBV Technologies"跑赢大市"评级，目标价从47美元升至55美元；康托·菲茨杰拉德：维持BioCryst制药"超配"评级，目标价从27美元升至29美元
07-01 10:40
分析师解读医疗健康企业：革命医药（RVMD）、福泰制药（VRTX）与Monopar Therapeutics Inc（MNPR）
近期3名医疗领域分析师分别对3只美股医疗股给出看涨评级，相关标的及核心信息如下： 瑞沃医药（RVMD）：Needham分析师阿米·法迪亚给出买入评级，目标价...
06-30 10:32
分析师解读医疗健康企业：美敦力（MDT）、Monopar Therapeutics Inc（MNPR）与Bio-Techne（TECH）
医疗保健领域近期释放乐观信号，3位分析师分别对美敦力（MDT）、莫诺帕制药公司（MNPR）、Bio-Techne（TECH）给出看涨评级。 相关个股评级及核心数...
06-30 10:32
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease
Monopar Therapeutics announced new Phase 3 FoCus trial analyses for ALXN1840, showing significant neurologic and global clinical improvement in Wilson disease patients compared to standard therapy. Key findings include superior outcomes on the UWDRS and CGI-I scales, with better safety and tolerability. These results support Monopar's planned NDA submission for ALXN1840 in mid-2026.
06-26 20:05
美股牛股 | 特朗普政府加码量子计算！QNT涨超13%；Backblaze涨超43%，与CoreWeave签署一项3.35亿美元协议
特朗普政府加码量子计算！ARQQ大涨超35%，QNT涨超13%；Backblaze涨超43%，与CoreWeave签署一项3.35亿美元的数据存储协议>>
06-24 15:51
Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
Monopar Therapeutics announced Phase 2 data for ALXN1840 at the EASL Congress 2026, showing stabilization of liver disease and improvement in neurological symptoms and quality of life for Wilson disease patients. The open-label trial involved 29 heavily pre-treated patients, with key findings including liver pathology stabilization, significant neurological and clinical improvements, and good tolerability. ALXN1840, a novel copper chelator, addre...
06-01 11:00
Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics announced its Q1 2026 financial results and business updates. The company remains on track to submit the NDA for ALXN1840 for Wilson Disease in mid-2026. Recent data from the FoCus trial showed greater neurologic benefits of ALXN1840 over standard of care. The company also presented results at major neurology and liver disease conferences. Cash and investments as of March 31, 2026, were $137.5 million, with net loss of $3.9 m...
05-14 18:00
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
Monopar Therapeutics announced positive Phase 3 FoCus trial results for ALXN1840 in Wilson disease patients with neurologic symptoms, showing greater neurologic benefit vs standard of care. At Week 48, 25% of SoC patients vs 9% of ALXN1840-treated patients experienced neurologic worsening (p=0.038), while 45% of ALXN1840 patients vs 32% of SoC patients showed improvement. ALXN1840 also demonstrated durable neurologic benefit over 3 years and a fa...
04-19 23:00
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16
Monopar Therapeutics press release (MNPR): Q4 GAAP EPS of -$0.61 misses by $0.16. Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million. More on Monopar Therap...
03-28 04:47
